Press Releases September 1, 2026 04:05 PM

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon Pharmaceuticals schedules presentations at three major investor conferences in September 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing transformative medicines, announced its management will present at three upcoming investor conferences in New York City during September 2026. The presentations will highlight the company's ongoing developments in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic, and other cardiometabolic indications.

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Management presentations scheduled at Citi Biopharma, Cantor Global Healthcare, and H.C. Wainwright Investment Conferences in September 2026.
  • Company pipeline includes drug candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic diseases.
  • Investor presentations accessible live and via replay on the company's website, increasing transparency and engagement.

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]


Risks

  • No new clinical or financial data provided, so uncertainty remains regarding the progress and efficacy of pipeline drug candidates.
  • Investor reactions may depend on management’s disclosures during the upcoming presentations; lack of strong positive updates could limit market enthusiasm.
  • Biopharmaceutical sector remains subject to regulatory risks and competitive pressures affecting development timelines and market potential.

More from Press Releases

iPower Opens New AI Era with Five-Year Services LOI Targeting $21.90 Million in Potential Annualized Services Oct 15, 2026 Carpenter Technology Corporation Announces General Counsel Succession Oct 14, 2026 SNDL to Report Third Quarter 2026 Financial Results on October 27, 2026 Oct 14, 2026 SixFifty, a Paychex Company, Launches Agentic HR Compliance Specialist Oct 13, 2026 Usio Announces Participation in Upcoming Investor Conferences Oct 13, 2026